Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Delgocitinib

Generic Name: Delgocitinib

Brand Names: Anzupgo

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₈N_₆O

CAS Number: 1263774-59-9

Unique Ingredient Identifier: 9L0Q8KK220

Overview

Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

Phase 3

Active, not recruiting

Posted: 2023/08/22

Sponsor:LEO Pharma

ID:NCT06004050

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

Phase 1

Completed

Posted: 2022/08/03

Sponsor:LEO Pharma

ID:NCT05486117

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

Phase 3

Completed

Posted: 2022/05/02

Sponsor:LEO Pharma

ID:NCT05355818

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Phase 2

Completed

Posted: 2022/04/18

Sponsor:LEO Pharma

ID:NCT05332366

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

Phase 3

Completed

Posted: 2022/02/28

Sponsor:LEO Pharma

ID:NCT05259722

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Delgocitinib Cream Shows "Super-Response" in Nearly Half of Chronic Hand Eczema Patients

3 months ago

Nearly 50% of patients with moderate to severe chronic hand eczema achieved a "deep response" with delgocitinib cream 20 mg/g by week 16, demonstrating significant relief from disease burden.

Phase 3 Trial Shows Delgocitinib Cream Effective for Adolescent Chronic Hand Eczema

3 months ago

LEO Pharma's delgocitinib 20 mg/g cream demonstrated significant efficacy in Phase 3 DELTA TEEN study for adolescents aged 12-17 with chronic hand eczema.

United Therapeutics' UKidney Xenotransplant Trial Receives FDA Clearance

4 months ago

United Therapeutics received FDA clearance for its IND application to begin clinical trials for UKidney, a gene-edited pig kidney, marking a significant step in xenotransplantation.

Emerging Treatments for Chronic Hand Eczema Show Promise in Closing Treatment Gap

5 months ago

New treatments for chronic hand eczema (CHE), including Sanofi and Regeneron's Dupixent and Leo Pharma's Anzupgo, are showing potential in addressing the current treatment gap. These therapies aim to manage both the disease and its symptoms without the major side effects associated with existing treatments. Leo Pharma's Anzupgo, in particular, has demonstrated superior efficacy and safety in recent clinical trials compared to existing options.

Leo Pharma's Anzupgo Receives UK Approval for Chronic Hand Eczema

6 months ago

Leo Pharma's Anzupgo has been approved in the UK for treating moderate-to-severe chronic hand eczema, expanding its market reach.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy